Naijian Li

Results reporting and primary endpoint achievement in interventional therapeutic trials for pleural mesothelioma, 2005–2025: a cross-sectional analysis

Pleural mesothelioma (PM) is a rare and aggressive malignancy in which therapeutic progress depends on a limited clinical trial evidence base. Although trial registration has improved transparency, the extent to which registered trials generate publicly available and clinically i...